Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 388

1.

Comparative effectiveness of TNF inhibitors and tocilizumab with and without conventional synthetic disease-modifying antirheumatic drugs in a pan-European observational cohort of bio-naïve patients with rheumatoid arthritis.

Lauper K, Mongin D, Iannone F, Kristianslund EK, Kvien TK, Nordström DC, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Gale SL, John M, Luder Y, Courvoisier DS, Gabay C.

Semin Arthritis Rheum. 2019 Jun 28. pii: S0049-0172(19)30203-3. doi: 10.1016/j.semarthrit.2019.06.020. [Epub ahead of print]

PMID:
31280937
2.

Drug retention of biological DMARD in rheumatoid arthritis patients: the role of baseline characteristics and disease evolution.

Lauper K, Mongin D, Alpizar-Rodriguez D, Codreanu C, Iannone F, Kristianslund EK, Kvien TK, Pavelka K, Pombo-Suarez M, Santos MJ, Gabay C, Finckh A, Courvoisier DS.

Rheumatology (Oxford). 2019 Jun 17. pii: kez221. doi: 10.1093/rheumatology/kez221. [Epub ahead of print]

PMID:
31209481
3.

Long-term safety and effectiveness of tocilizumab in patients with rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: an open-label study close to clinical practice.

Bykerk VP, Östör AJK, Alvaro-Gracia J, Pavelka K, Román Ivorra JA, Nurmohamed MT, Luder Y, Sidiropoulos PNM, Devenport J, Sibilia J.

Clin Rheumatol. 2019 Apr 26. doi: 10.1007/s10067-019-04535-z. [Epub ahead of print]

PMID:
31028551
4.

Serum visfatin levels in patients with axial spondyloarthritis and their relationship to disease activity and spinal radiographic damage: a cross-sectional study.

Hulejová H, Kropáčková T, Bubová K, Kryštůfková O, Filková M, Mann H, Forejtová Š, Tomčík M, Vencovský J, Pavelka K, Šenolt L.

Rheumatol Int. 2019 Jun;39(6):1037-1043. doi: 10.1007/s00296-019-04301-z. Epub 2019 Apr 25.

PMID:
31025138
5.

Functional Characterization of Clinically-Relevant Rare Variants in ABCG2 Identified in a Gout and Hyperuricemia Cohort.

Toyoda Y, Mančíková A, Krylov V, Morimoto K, Pavelcová K, Bohatá J, Pavelka K, Pavlíková M, Suzuki H, Matsuo H, Takada T, Stiburkova B.

Cells. 2019 Apr 18;8(4). pii: E363. doi: 10.3390/cells8040363.

6.

Cross-sectional study of patients with axial spondyloarthritis fulfilling imaging arm of ASAS classification criteria: baseline clinical characteristics and subset differences in a single-centre cohort.

Bubová K, Forejtová Š, Zegzulková K, Gregová M, Hušáková M, Filková M, Hořínková J, Gatterová J, Tomčík M, Szczuková L, Pavelka K, Šenolt L.

BMJ Open. 2019 Apr 2;9(4):e024713. doi: 10.1136/bmjopen-2018-024713.

7.

An open-label extension study to demonstrate long-term safety and efficacy of ABP 501 in patients with rheumatoid arthritis.

Cohen S, Pablos JL, Pavelka K, Müller GA, Matsumoto A, Kivitz A, Wang H, Krishnan E.

Arthritis Res Ther. 2019 Mar 29;21(1):84. doi: 10.1186/s13075-019-1857-3.

8.

The impact of dysfunctional variants of ABCG2 on hyperuricemia and gout in pediatric-onset patients.

Stiburkova B, Pavelcova K, Pavlikova M, Ješina P, Pavelka K.

Arthritis Res Ther. 2019 Mar 20;21(1):77. doi: 10.1186/s13075-019-1860-8.

9.

Metabolites of C-reactive protein and vimentin are associated with disease activity of axial spondyloarthritis.

Siebuhr AS, Hušaková M, Forejtová S, Zegzulková K, Tomčik M, Urbanová M, Grobelná K, Gatterová J, Bay-Jensen AC, Pavelka K.

Clin Exp Rheumatol. 2019 May-Jun;37(3):358-366. Epub 2019 Feb 11.

10.

S100A11 (calgizzarin) is released by circulating mononuclear cells and its elevated plasma levels distinguish systemic lupus erythematosus patients from healthy individuals.

Cerezo LA, Šumová B, Hulejová H, Štorkánová H, Szczuková L, Tomčík M, Bečvář R, Pavelka K, Vencovský J, Závada J, Šenolt L.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):338-339. Epub 2019 Feb 4. No abstract available.

11.

Prevalence and distribution of cartilage damage at the metacarpal head level in rheumatoid arthritis and osteoarthritis: an ultrasound study.

Hurnakova J, Filippucci E, Cipolletta E, Di Matteo A, Salaffi F, Carotti M, Draghessi A, Di Donato E, Di Carlo M, Lato V, Horvath R, Komarc M, Pavelka K, Grassi W.

Rheumatology (Oxford). 2019 Jul 1;58(7):1206-1213. doi: 10.1093/rheumatology/key443.

PMID:
30690561
12.

Pro-inflammatory S100A11 is elevated in inflammatory myopathies and reflects disease activity and extramuscular manifestations in myositis.

Andrés Cerezo L, Hulejová H, Šumová B, Kropáčková T, Kryštůfková O, Klein M, Mann HF, Zámečník J, Pecha O, Pavelka K, Vencovský J, Šenolt L.

Cytokine. 2019 Apr;116:13-20. doi: 10.1016/j.cyto.2018.12.023. Epub 2019 Jan 23.

PMID:
30684913
13.

Real world use of secukinumab for treatment of axial spondyloarthritis and psoriatic arthritis: nationwide results from the ATTRA registry.

Mann HF, Závada J, Šenolt L, Bubová K, Nekvindová L, Křístková Z, Horák P, Vencovský J, Pavelka K; and the ATTRA Registry.

Clin Exp Rheumatol. 2019 Mar-Apr;37(2):342-343. Epub 2019 Jan 4. No abstract available.

14.

Comparative effectiveness of subcutaneous tocilizumab versus intravenous tocilizumab in a pan-European collaboration of registries.

Lauper K, Mongin D, Iannone F, Klami Kristianslund E, Kvien TK, Nordström D, Pavelka K, Pombo-Suarez M, Rotar Z, Santos MJ, Codreanu C, Lukina G, Courvoisier DS, Gabay C.

RMD Open. 2018 Nov 5;4(2):e000809. doi: 10.1136/rmdopen-2018-000809. eCollection 2018.

15.

Circulating S100 proteins effectively discriminate SLE patients from healthy controls: a cross-sectional study.

Šumová B, Cerezo LA, Szczuková L, Nekvindová L, Uher M, Hulejová H, Moravcová R, Grigorian M, Pavelka K, Vencovský J, Šenolt L, Závada J.

Rheumatol Int. 2019 Mar;39(3):469-478. doi: 10.1007/s00296-018-4190-2. Epub 2018 Nov 3.

PMID:
30392117
16.

Non-pharmacological Effects in Switching Medication: The Nocebo Effect in Switching from Originator to Biosimilar Agent.

Kristensen LE, Alten R, Puig L, Philipp S, Kvien TK, Mangues MA, van den Hoogen F, Pavelka K, Vulto AG.

BioDrugs. 2018 Oct;32(5):397-404. doi: 10.1007/s40259-018-0306-1.

17.

Smoking and response to rituximab in rheumatoid arthritis: results from an international European collaboration.

Chatzidionysiou K, Lukina G, Gabay C, Hetland ML, Hauge EM, Pavelka K, Nordström D, Canhão H, Tomsic M, Rotar Z, Lie E, Kvien TK, van Vollenhoven RF, Saevarsdottir S.

Scand J Rheumatol. 2019 Jan;48(1):17-23. doi: 10.1080/03009742.2018.1466363. Epub 2018 Sep 27.

PMID:
30260261
18.

Lower serum clusterin levels in patients with erosive hand osteoarthritis are associated with more pain.

Kropáčková T, Šléglová O, Růžičková O, Vencovský J, Pavelka K, Šenolt L.

BMC Musculoskelet Disord. 2018 Jul 27;19(1):264. doi: 10.1186/s12891-018-2179-3.

19.

Factors associated with the orthopaedic surgeon's decision to recommend total joint replacement in hip and knee osteoarthritis: an international cross-sectional study of 1905 patients.

Huynh C, Puyraimond-Zemmour D, Maillefert JF, Conaghan PG, Davis AM, Gunther KP, Hawker G, Hochberg MC, Kloppenburg M, Lim K, Lohmander LS, Mahomed NN, March L, Pavelka K, Punzi L, Roos EM, Sanchez-Riera L, Singh JA, Suarez-Almazor ME, Dougados M, Gossec L.

Osteoarthritis Cartilage. 2018 Oct;26(10):1311-1318. doi: 10.1016/j.joca.2018.06.013. Epub 2018 Jul 11.

PMID:
30017727
20.

Entheseal involvement in patients with systemic lupus erythematosus: an ultrasound study.

Di Matteo A, Filippucci E, Cipolletta E, Satulu I, Hurnakova J, Lato V, De Angelis R, Horvath R, Pavelka K, Salaffi F, Grassi W.

Rheumatology (Oxford). 2018 Oct 1;57(10):1822-1829. doi: 10.1093/rheumatology/key189.

PMID:
29982722
21.

Chronic Low Back Pain: Current Pharmacotherapeutic Therapies and a New Biological Approach.

Pavelka K, Jarosova H, Sleglova O, Svobodova R, Votavova M, Milani L, Prochazka Z, Kotlarova L, Kostiuk P, Sliva J, Meroni AM.

Curr Med Chem. 2019;26(6):1019-1026. doi: 10.2174/0929867325666180514102146. Review.

PMID:
29756567
22.

Correction to: Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N.

Clin Rheumatol. 2018 Jul;37(7):2017-2018. doi: 10.1007/s10067-018-4131-1.

PMID:
29752584
23.

Comparative effectiveness of tocilizumab versus TNF inhibitors as monotherapy or in combination with conventional synthetic disease-modifying antirheumatic drugs in patients with rheumatoid arthritis after the use of at least one biologic disease-modifying antirheumatic drug: analyses from the pan-European TOCERRA register collaboration.

Lauper K, Nordström DC, Pavelka K, Hernández MV, Kvien TK, Kristianslund EK, Santos MJ, Rotar Ž, Iannone F, Codreanu C, Lukina G, Gale SL, Sarsour K, Luder Y, Courvoisier DS, Gabay C.

Ann Rheum Dis. 2018 Sep;77(9):1276-1282. doi: 10.1136/annrheumdis-2017-212845. Epub 2018 May 5.

PMID:
29730637
24.

Serum calprotectin may reflect inflammatory activity in patients with active rheumatoid arthritis despite normal to low C-reactive protein.

Hurnakova J, Hulejova H, Zavada J, Komarc M, Cerezo LA, Mann H, Vencovsky J, Pavelka K, Senolt L.

Clin Rheumatol. 2018 Aug;37(8):2055-2062. doi: 10.1007/s10067-018-4091-5. Epub 2018 Apr 14.

PMID:
29656372
25.

Regional differences in baseline disease activity and remission rates following golimumab treatment for RA: results from the GO-MORE trial.

Durez P, Pavelka K, Lazaro MA, Garcia-Kutzbach A, Moots RJ, Amital H, Govoni M, Vastesaeger N.

Clin Rheumatol. 2018 May;37(5):1417-1420. doi: 10.1007/s10067-018-4074-6. Epub 2018 Apr 2. Erratum in: Clin Rheumatol. 2018 May 12;:.

PMID:
29611083
26.

[Treat to target in gouty arthritis].

Pavelka K.

Vnitr Lek. Spring 2018;64(2):185-190. Czech.

PMID:
29595284
27.

Efficacy, safety, and tolerability of secukinumab in patients with active ankylosing spondylitis: a randomized, double-blind phase 3 study, MEASURE 3.

Pavelka K, Kivitz A, Dokoupilova E, Blanco R, Maradiaga M, Tahir H, Pricop L, Andersson M, Readie A, Porter B.

Arthritis Res Ther. 2017 Dec 22;19(1):285. doi: 10.1186/s13075-017-1490-y.

28.

Mapping Quality of Life (EQ-5D) from DAPsA, Clinical DAPsA and HAQ in Psoriatic Arthritis.

Mlcoch T, Tuzil J, Sedova L, Stolfa J, Urbanova M, Suchy D, Smrzova A, Jircikova J, Hrnciarova T, Pavelka K, Dolezal T.

Patient. 2018 Jun;11(3):329-340. doi: 10.1007/s40271-017-0285-1.

PMID:
29164493
29.

[Osteoarthritis as part of metabolic syndrome?]

Pavelka K.

Vnitr Lek. Fall 2017;63(10):707-711. Review. Czech.

PMID:
29127754
30.

Biomarkers of hand osteoarthritis.

Lennerová T, Pavelka K, Šenolt L.

Rheumatol Int. 2018 May;38(5):725-735. doi: 10.1007/s00296-017-3864-5. Epub 2017 Nov 2. Review.

PMID:
29098370
31.

Functional non-synonymous variants of ABCG2 and gout risk.

Stiburkova B, Pavelcova K, Zavada J, Petru L, Simek P, Cepek P, Pavlikova M, Matsuo H, Merriman TR, Pavelka K.

Rheumatology (Oxford). 2017 Nov 1;56(11):1982-1992. doi: 10.1093/rheumatology/kex295.

PMID:
28968913
32.

Association between circulating miRNAs and spinal involvement in patients with axial spondyloarthritis.

Prajzlerová K, Grobelná K, Hušáková M, Forejtová Š, Jüngel A, Gay S, Vencovský J, Pavelka K, Šenolt L, Filková M.

PLoS One. 2017 Sep 22;12(9):e0185323. doi: 10.1371/journal.pone.0185323. eCollection 2017.

33.

Changes of patient-reported outcomes and protein fingerprint biomarkers after exercise therapy for axial spondyloarthritis.

Husakova M, Siebuhr AS, Pavelka K, Spiritovic M, Bay-Jensen AC, Levitova A.

Clin Rheumatol. 2019 Jan;38(1):173-179. doi: 10.1007/s10067-017-3802-7. Epub 2017 Aug 30.

PMID:
28856518
34.

Relationship between serum calprotectin (S100A8/9) and clinical, laboratory and ultrasound parameters of disease activity in rheumatoid arthritis: A large cohort study.

Hurnakova J, Hulejova H, Zavada J, Hanova P, Komarc M, Mann H, Klein M, Sleglova O, Olejarova M, Forejtova S, Ruzickova O, Vencovsky J, Pavelka K, Senolt L.

PLoS One. 2017 Aug 23;12(8):e0183420. doi: 10.1371/journal.pone.0183420. eCollection 2017.

35.

Treatment of atlanto-axial subluxation secondary to rheumatoid arthritis by short segment stabilization with polyaxial screws.

Vanek P, Bradac O, de Lacy P, Pavelka K, Votavova M, Benes V.

Acta Neurochir (Wien). 2017 Sep;159(9):1791-1801. doi: 10.1007/s00701-017-3274-1. Epub 2017 Jul 27.

PMID:
28752203
36.

Interleukin-20 is triggered by TLR ligands and associates with disease activity in patients with rheumatoid arthritis.

Šenolt L, Prajzlerová K, Hulejová H, Šumová B, Filková M, Veigl D, Pavelka K, Vencovský J.

Cytokine. 2017 Sep;97:187-192. doi: 10.1016/j.cyto.2017.06.009. Epub 2017 Jun 26.

PMID:
28662439
37.

Maintenance of remission with combination etanercept-DMARD therapy versus DMARDs alone in active rheumatoid arthritis: results of an international treat-to-target study conducted in regions with limited biologic access.

Pavelka K, Akkoç N, Al-Maini M, Zerbini CAF, Karateev DE, Nasonov EL, Rahman MU, Pedersen R, Dinh A, Shen Q, Vasilescu R, Kotak S, Mahgoub E, Vlahos B.

Rheumatol Int. 2017 Sep;37(9):1469-1479. doi: 10.1007/s00296-017-3749-7. Epub 2017 Jun 9.

PMID:
28597306
38.

Efficacy and safety of the biosimilar ABP 501 compared with adalimumab in patients with moderate to severe rheumatoid arthritis: a randomised, double-blind, phase III equivalence study.

Cohen S, Genovese MC, Choy E, Perez-Ruiz F, Matsumoto A, Pavelka K, Pablos JL, Rizzo W, Hrycaj P, Zhang N, Shergy W, Kaur P.

Ann Rheum Dis. 2017 Oct;76(10):1679-1687. doi: 10.1136/annrheumdis-2016-210459. Epub 2017 Jun 5.

39.

Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B.

PLoS One. 2017 Jun 5;12(6):e0179308. doi: 10.1371/journal.pone.0179308. eCollection 2017.

40.

Pharmaceutical-grade Chondroitin sulfate is as effective as celecoxib and superior to placebo in symptomatic knee osteoarthritis: the ChONdroitin versus CElecoxib versus Placebo Trial (CONCEPT).

Reginster JY, Dudler J, Blicharski T, Pavelka K.

Ann Rheum Dis. 2017 Sep;76(9):1537-1543. doi: 10.1136/annrheumdis-2016-210860. Epub 2017 May 22.

41.

The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study.

Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B.

PLoS One. 2017 Apr 27;12(4):e0175207. doi: 10.1371/journal.pone.0175207. eCollection 2017. Erratum in: PLoS One. 2017 Jun 5;12 (6):e0179308.

42.

Calgizzarin (S100A11): a novel inflammatory mediator associated with disease activity of rheumatoid arthritis.

Andrés Cerezo L, Šumová B, Prajzlerová K, Veigl D, Damgaard D, Nielsen CH, Pavelka K, Vencovský J, Šenolt L.

Arthritis Res Ther. 2017 Apr 26;19(1):79. doi: 10.1186/s13075-017-1288-y.

43.

Erratum to: Diacerein: Benefits, Risks and Place in the Management of Osteoarthritis. An Opinion-Based Report from the ESCEO.

Pavelka K, Bruyère O, Cooper C, Kanis JA, Leeb BF, Maheu E, Martel-Pelletier J, Monfort J, Pelletier JP, Rizzoli R, Reginster JY.

Drugs Aging. 2017 May;34(5):413. doi: 10.1007/s40266-017-0457-7. No abstract available.

PMID:
28349413
44.

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update.

Smolen JS, Landewé R, Bijlsma J, Burmester G, Chatzidionysiou K, Dougados M, Nam J, Ramiro S, Voshaar M, van Vollenhoven R, Aletaha D, Aringer M, Boers M, Buckley CD, Buttgereit F, Bykerk V, Cardiel M, Combe B, Cutolo M, van Eijk-Hustings Y, Emery P, Finckh A, Gabay C, Gomez-Reino J, Gossec L, Gottenberg JE, Hazes JMW, Huizinga T, Jani M, Karateev D, Kouloumas M, Kvien T, Li Z, Mariette X, McInnes I, Mysler E, Nash P, Pavelka K, Poór G, Richez C, van Riel P, Rubbert-Roth A, Saag K, da Silva J, Stamm T, Takeuchi T, Westhovens R, de Wit M, van der Heijde D.

Ann Rheum Dis. 2017 Jun;76(6):960-977. doi: 10.1136/annrheumdis-2016-210715. Epub 2017 Mar 6. Review.

45.

Use of Intraarticular Hyaluronic Acid in the Management of Knee Osteoarthritis in Clinical Practice.

Cooper C, Rannou F, Richette P, Bruyère O, Al-Daghri N, Altman RD, Brandi ML, Collaud Basset S, Herrero-Beaumont G, Migliore A, Pavelka K, Uebelhart D, Reginster JY.

Arthritis Care Res (Hoboken). 2017 Sep;69(9):1287-1296. doi: 10.1002/acr.23204. Epub 2017 Aug 8. Review. No abstract available.

46.

Rituximab Retreatment in Rheumatoid Arthritis in a Real-life Cohort: Data from the CERERRA Collaboration.

Chatzidionysiou K, Lie E, Lukina G, Hetland ML, Hauge EM, Pavelka K, Gabay C, Scherer A, Nordström D, Canhao H, Santos MJ, Tomsic M, Rotar Z, Hernández MV, Gomez-Reino J, Ancuta I, Kvien TK, van Vollenhoven R.

J Rheumatol. 2017 Feb;44(2):162-169. doi: 10.3899/jrheum.160460. Epub 2017 Jan 15.

PMID:
28089978
47.

The relationship between synovitis quantified by an ultrasound 7-joint inflammation score and physical disability in rheumatoid arthritis - a cohort study.

Závada J, Hánová P, Hurňáková J, Szczuková L, Uher M, Forejtová Š, Klein M, Mann H, Olejárová M, Růžičková O, Šléglová O, Hejduk K, Pavelka K.

Arthritis Res Ther. 2017 Jan 13;19(1):5. doi: 10.1186/s13075-016-1208-6.

48.

A 12-week randomized, double-blind, placebo-controlled multicenter study of choline-stabilized orthosilicic acid in patients with symptomatic knee osteoarthritis.

Geusens P, Pavelka K, Rovensky J, Vanhoof J, Demeester N, Calomme M, Vanden Berghe D.

BMC Musculoskelet Disord. 2017 Jan 5;18(1):2. doi: 10.1186/s12891-016-1370-7.

49.

Body mass does not impact the clinical response to intravenous abatacept in patients with rheumatoid arthritis. Analysis from the "pan-European registry collaboration for abatacept (PANABA).

Iannone F, Courvoisier DS, Gottenberg JE, Hernandez MV, Lie E, Canhão H, Pavelka K, Hetland ML, Turesson C, Mariette X, Choquette D, Finckh A.

Clin Rheumatol. 2017 Apr;36(4):773-779. doi: 10.1007/s10067-016-3505-5. Epub 2016 Dec 14.

PMID:
27966068
50.

[15 years experience with biological therapy of inflammatory rheumatic diseases in Czech national register ATTRA].

Pavelka K, Šedová L, Hejduk K, Dušek L.

Cas Lek Cesk. Fall 2016;155(6):285-293. Czech.

PMID:
27917631

Supplemental Content

Loading ...
Support Center